Clinical Trial Search

Primary: Concentration (pg/ml) of CXCL8 Cytokine in Cell Supernatant After Stimulation (IFN/TNF or IL13) and Treatment (VR588, FP or CP) Conditions in ALI Cultured Epithelial…

Primary: Number of Participants With Emergent Agitation — 16; 24 Participants

Primary: Rate of First or Only Clinical Episode of Plasmodium Falciparum (P. Falciparum) Malaria Infection (CPFMI), or Clinical Malaria Episode of Primary Case Definition…

Primary: Fruit and Vegetable Intakes (Self-report, Questionnaire Assessment) — 3.8; 2.6; 5.2; 4.0 FV portions per day

Primary: Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts — 11 percentage of participants

Primary: Tear Breakup Time Average — 3.3; 3.0; 4.1; 4.5 Seconds — p=0.3

Primary: Change in Sleep Quality — 33.2; 0; -35; 0 minutes

Primary: Number of Participants With Uptake of Genetic Counseling for Those at Risk of Hereditary Conditions at 1 Year — 571; 49; 32; 31 Participants

Primary: Implant Survival — 42 Implants

Primary: Number of HER2 Negative, Positive, or Equivocal Participants With Either Negative or Positive Tumor Readings — 5; 1; 2; 0 participants

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 78.1; 72.2; 80.0; 85.7 percentage of participants

Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 4 Participants

Primary: Number of Adenomas Detected Per Colonoscopy (APC). — 1.63; 1.51 adenomas

Primary: Objective Response Rate (ORR) — 0 Participants

Primary: Number of Components of the ICU Recovery Program Received — 2; 1 interventions